

Focus Group Meeting on Bacteriophages

11 May 2023, Amsterdam/virtual

Chair: Jacqueline Poot

Programme

09:30	Introduction and welcome (5')
	Jacqueline Poot (Chair of Novel Therapies and Technologies Working Party)
09:35	Setting the scene: introduction on the background and expected outputs for the meeting (10^\prime)
	Susana Casado (Vice-chair of Novel Therapies and Technologies Working Party)
Session I: Guideline on quality, safety and efficacy of veterinary medicinal products specifically designed for phage therapy	
09:45	Presentation on quality aspects (30')
	Martin Bronislaw Oleksiewicz (Danish Medicines Agency)
10.15	Ou an diagnosia n
10:15	Open discussion
10:45	Coffee break
11:00	Presentation on safety aspects (30')
	Sandra-Maria Wienhold (Federal Office of Consumer Protection and Food Safety)
11:30	Open discussion
12:00	Lunch break
13:15	Presentation on efficacy aspects (30')
	Belén Gutiérrez Soriano (Spanish Agency of Medicines and Medical Devices)
13:45	Open discussion
14:15	
17.13	EDQM perspective on Ph. Eur. activities on bacteriophages (20')
	Olga Kolaj-Robin (European Directorate for the Quality of Medicines & HealthCare)
14:35	Coffe break



Session II: Case studies on bacteriophages

14:50	Case studies on bacteriophages (30') Frédéric Klein (Federal Agency for Medicines and Health Products) Susana Casado (Spanish Agency of Medicines and Medical Devices)
15:20	Open discussion
15:50	Conclusions and closing remarks (40') Jacqueline Poot (CBG-MEB Medicines Evaluation Board)

Speakers

Belén Gutiérrez Soriano Scientific assessor at the Spanish Agency of Medicines and

Medical Devices; Member of the Operational Expert Group on

bacteriophages

Frédéric Klein Scientific expert at the Federal Agency for Medicines and Health

Products; Coordinator of the Operational Expert Group on bacteriophages; Member of Novel Therapies and Technologies Working Party; Alternate member of the EMA Committee for

Medicinal Products for Veterinary Use

Jacqueline Poot Clinical assessor at the CBG-MEB Medicines Evaluation Board;

Chair of Novel Therapies and Technologies Working Party; Member of the EMA Committee for Medicinal Products for

Veterinary Use

Martin Bronislaw Oleksiewicz Head consultant at the Danish Medicines Agency; Member of the

Operational Expert Group on bacteriophages

Olga Kolaj-Robin Scientific officer at European Directorate for the Quality of

Medicines & HealthCare; Coordinator of the European

Pharmacopoeia Groups of Experts and Working Parties in the area of Biological and Biotechnological Substances, Antibiotics,

Gene Therapy Products and Phage Therapy

Sandra-Maria Wienhold Scientific assessor at the Federal Office of Consumer Protection

and Food Safety; Member of the Operational Expert Group on

bacteriophages

Susana Casado Head of Unit of Immuno-Bio Veterinary Medicines at the Spanish

Agency of Medicines and Medical Devices; Coordinator of the Operational Expert Group on bacteriophages; Vice-Chair of

Novel Therapies and Technologies Working Party